Pharma brand revitalisation in 2026 demands bold shifts: target untapped rural markets, prioritise high-growth brands, optimise P&L, leverage digital channels, and design efficient routes-to-market for sustained growth.

Unlock growth in underleveraged pharma brands by optimizing portfolios, refreshing value propositions, targeting extra-urban markets via hub-and-spoke models, enhancing field force productivity, and leveraging digital strategies.